Literature DB >> 9383735

Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2.

X M Lam1, J Y Yang, J L Cleland.   

Abstract

Recombinant humanized monoclonal antibody HER2, rhuMAb HER2, in liquid formulations undergoes oxidation when exposed to intense light and elevated temperatures (30 & 40 degrees C). Met-255 in the heavy chain of the Fc region of the antibody is the primary site of oxidation. Met-431 of the Fc fragment can also be oxidized under extreme conditions. The amount of oxidation was determined by cleaving the Fab and Fc fragments by papain digestion, and the oxidized Fc fragment was detected by hydrophobic interaction chromatography. Oxidation of rhuMAb HER2 was also formulation dependent. The presence of NaCl in the rhuMAb HER2 formulation caused an increase in oxidation at higher temperatures after contact with stainless steel containers or stainless steel components in the filling process. The corrosion of stainless steel by chloride ions at the low pH of the formulation buffer generated iron ions that catalyzed methionine oxidation in rhuMAb HER2. Temperature-induced oxidation of rhuMAb HER2 occurred by the formation of free radicals, and light-induced oxidation of rhuMAb HER2 occurred via single oxygen pathway. Antioxidants, such as methionine, sodium thiosulfate, catalase, or platinum, prevented Met oxidation in rhuMAb HER2, presumably as free radicals or oxygen scavengers. The minimum effective levels (molar ratios of protein to antioxidant) required to inhibit temperature-induced oxidation were 1:5 and 1:25 for methionine and thiosulfate, respectively. A thiosulfate adduct of rhuMAb HER2 was observed by cation-exchange chromatography. These studies demonstrate that stoichiometric amounts of methionine and thiosulfate are sufficient to eliminate temperature-induced oxidation of rhuMAb HER2 caused by free radicals that were generated by the presence of metal ion and peroxide impurities in the formulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9383735     DOI: 10.1021/js970143s

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  62 in total

Review 1.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

Review 2.  High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability.

Authors:  Rajoshi Chaudhuri; Yuan Cheng; C Russell Middaugh; David B Volkin
Journal:  AAPS J       Date:  2013-10-31       Impact factor: 4.009

Review 3.  Oxidation of therapeutic proteins and peptides: structural and biological consequences.

Authors:  Riccardo Torosantucci; Christian Schöneich; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

4.  X-ray spectroscopic approaches to the investigation and characterization of photochemical processes.

Authors:  Pierre Kennepohl; Erik C Wasinger; Serena DeBeer George
Journal:  J Synchrotron Radiat       Date:  2009-06-17       Impact factor: 2.616

5.  Chemical modifications in therapeutic protein aggregates generated under different stress conditions.

Authors:  Quanzhou Luo; Marisa K Joubert; Riki Stevenson; Randal R Ketchem; Linda O Narhi; Jette Wypych
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

Review 6.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

7.  Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration.

Authors:  Sorina Morar-Mitrica; Manasi Puri; Alexandra Beumer Sassi; Joshua Fuller; Ping Hu; George Crotts; Douglas Nesta
Journal:  MAbs       Date:  2015       Impact factor: 5.857

8.  Disruption of Escherichia coli amyloid-integrated biofilm formation at the air-liquid interface by a polysorbate surfactant.

Authors:  Cynthia Wu; Ji Youn Lim; Gerald G Fuller; Lynette Cegelski
Journal:  Langmuir       Date:  2013-01-09       Impact factor: 3.882

Review 9.  Effects of glycosylation on the stability of protein pharmaceuticals.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

10.  Mitigation of Oxidation in Therapeutic Antibody Formulations: a Biochemical Efficacy and Safety Evaluation of N-Acetyl-Tryptophan and L-Methionine.

Authors:  Michelle Z Dion; Danielle Leiske; Vikas K Sharma; Christina L Zuch de Zafra; Cleo M Salisbury
Journal:  Pharm Res       Date:  2018-10-02       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.